| | Gout | | | Hyperuricemia and Gout: An Overview of Practice Management and Emerging Therapies
Overview
Is hyperuricemia another door to the metabolic syndrome? This activity will focus on hyperuricemia and gout and will examine the latest guidance around treating patients in the primary care practice. The program will include a focus on the latest guidelines as well as applying the learning into everyday practice dynamics.
Objectives
List the key components of a differential diagnosis for gout based on clinical history and physical examination elements
Develop a treatment plan, which includes behavioral modification and pharmacologic strategies
Faculty
Robert A. Terkeltaub, MD
Chief of Rheumatology
Veterans Administration Medical Center
Professor of Medicine and Associate Division Director
University of California, San Diego
San Diego, CA
Joseph A. Lieberman III, MD, MPH
Professor of Family Medicine
Jefferson Medical College
Thomas Jefferson University
Associate Editor, Delaware Medical Journal
Philadelphia, PA
| | | Meningococcal Disease | | | Preventing Meningococcal Disease: Defining Risk and Differentiating Serogroups
Overview
This program is designed to provide a critical update to physicians on the best measures currently available to prevent meningococcal disease in their patients. This includes the latest evidence-based research on specific serotypes of meningococcus and the specific vaccines directed against them, the efficacy and safety of these vaccines, the most recent guidelines of the CDC and ACIP, and the most effective means of communicating with their patients and achieving the highest rates of vaccination possible against this disease.
Objectives
Identify patient groups at high risk for meningococcal infection and employ effective screening procedures and routine review of immunization records to ensure appropriate vaccination rates
Understand the correspondence between the strains or serogroups of N meningitidis prevalent in the U.S. and the characteristics such as vaccine class (polysaccharide, conjugate), specificity for one or more strains, efficacy, and safety of the currently approved vaccines
Faculty
Lee H. Harrison, MD
Professor and Head
Infectious Diseases Epidemiology Research Unit
University of Pittsburgh
Pittsburgh, PA
Todd H. Wolynn, MD, MMM, FAAP
General Pediatrician
Pediatric Alliance, PC
Medical Director
Atlantic Health Partners
Pittsburgh, PA
| | | Atherothrombosis | | | Prevent The Event: Defining The Role of Oral Antiplatelet Therapy in Atherothrombosis
Overview
Atherothrombosis is the leading cause of death worldwide and the underlying process in the etiology of acute coronary syndrome (ACS), stroke and vascular death. Cardiovascular risk factors such as obesity, the metabolic syndrome, diabetes mellitus, hypertension, smoking and other "lifestyle" risks contribute to this pandemic of atherothrombotic disease. Patients with ACS, stroke/TIA and PAD (peripheral arterial disease), present major challenges to the primary care clinician in terms of managing CV risk factors and prevention of a second event. This lecture will overview current studies and treatment guidelines for PAD, ACS and Stroke and explore the role of primary care in long-term treatment of these patients.
Objectives
Describe 3 clinical conditions in which dual antiplatelet therapy is recommended
Name 5 treatment recommendations for reduction of global CV risk
Faculty
Martin W. Schwarze, DO, FACC
Clinical Professor of Medicine
St. Louis University School of Medicine
St. Louis, MO
F. Wilford Germino, MD, FAHA
| | | Diabetes Spotlight | | | Spotlight on Diabetes: Managing Patients in Primary Care
Overview
Leading clinicians will offer an interactive, case-based approach to the diagnosis and treatment of patients with pre-diabetes and diabetes to review the best methods to prevent disease onset and optimal treatment regimens to manage progression.
Objectives
Define pre-diabetes and monitor its development through the measurement of impaired fasting glucose (IFG) or impaired glucose tolerance (IGT)
Identify CVD risk factors in diabetic patients and be familiar with therapeutic goals and treatment strategies for dyslipidemia, hypertension, metabolic syndrome and obesity
Identify how ethnicity plays a role in CVD risk stratification
Identify strategies for the treatment of the diabetic patient with obesity including lifestyle changes, therapeutic strategies and surgical interventions
Devise a strategy for the use of insulin in the primary care practice, including short-acting and long-acting analogues, combination therapy and delivery devices
Describe incretin biology and current and emerging incretin therapeutics, including combination therapy, in the treatment of type 2 diabetes and explain the side effects of medication, which will improve patient compliance
Faculty
Ronald A. Codario, MD, FACP
Clinical Instructor in Medicine
Thomas Jefferson University Hospital
University of Pennsylvania Health System
Philadelphia, PA
James Gavin III, MD, PhD
Clinical Professor of Medicine
Emory University School of Medicine
Atlanta, GA
Seth Braunstein, MD, PhD
Associate Professor of Medicine
University of Pennsylvania School of Medicine
Philadelphia, PA
Thomas M. Flood, MD, FACE
Georgia Center for Diabetes
Atlanta, GA
| | | Dyslipidemia | | | Early and Aggressive LDL-C Management: Perspectives on Commonly Asked Questions
Overview
This presentation will address early and aggressive LDL-C management and the clinical challenges of goal attainment. Clinicians will be provided with pathways and knowledge to help them improve their patient outcomes by goal attainment of the healthy lipid profile.
Discussion will be applicable to clinicians' practice including lifestyle changes of diet and exercise, along with pharmacologic treatment options available for lipid management in order to give the appropriate tools to get patients to their true LDL goals.
Objectives
Understand the key tenets of assessing and managing dyslipidemia in clinical practice and the current evidence regarding the safety and efficacy of available LDL-C lowering therapies
Identify at least 2 lipid lowering strategies to initiate and tailor comprehensive management treatment plans for patients with high LDL-C in order to reach and maintain targeted goals
Faculty
Amit Khera, MD, MSc, FACC
Assistant Professor, Division of Cardiology
University of Texas, Southwestern Medical School
Dallas, TX
David A. Leaf, MD, MPH
Professor of Medicine
UCLA School of Medicine
Los Angeles, CA
| | | Pain Management | | | Management of Patients with Refractory Chronic Low Back Pain in the Primary Care Setting
Overview
Patients with refractory chronic low back pain represent a clinical challenge to primary care practitioners. Worsening persistent pain, an array of comorbid conditions, and loss of function coupled with a lack of evidence for treatment can create a clinical conundrum. Learn how to improve the longitudinal management of patients presenting to your practice with this ubiquitous and demanding condition.
Objectives
Select validated tools for use in comprehensive assessment and risk-stratification of patients with refractory chronic low back pain treated with opioids
Devise a treatment plan specific to the needs of chronic low back pain patients that demonstrate an understanding of recommended guidelines published jointly by the ACP/APS
Faculty
Gerald M. Sacks, MD
Director of Pain Management
Saint John's Health Center
Santa Monica, CA
| | | Insomnia | | | Managing Insomnia in Primary Care: Understanding Current and Developing Pharmacological and Nonpharmacological Therapies
Overview
Insomnia, defined as complaints of disturbed sleep in the presence of adequate opportunity and circumstance for sleep, is the most common adult sleep pathology. Besides cognition, other pathologic processes have been deleteriously associated with insomnia, including cardiovascular morbidity and glycemic control. The latest evidence about sleep pathology will be presented, including spectral analysis that indicates sleep patterns, including slow wave sleep, are important, rather than just total sleep time. Nonpharmacologic approaches, as well as current and developing pharmacotherapies used to address these sleep pathologies will be described.
Objectives
Identify the underlying causes and comorbid conditions of insomnia for increased confidence in treatment
Assess the current and developing nonpharmacologic and pharmacologic approaches to the management of primary and comorbid insomnia
Faculty
David Neubauer, MD
Associate Professor
Department of Psychiatry
Johns Hopkins University School of Medicine
Associate Director
Johns Hopkins Sleep Disorders Center
Baltimore, MD
Paul P. Doghramji, MD, FAAFP
Family Physician
Collegeville Family Practice
Medical Director of Health Services, Ursinus College
Collegeville, PA
| | | Rhinitis | | | Diagnostic Work-up and Management of Histamine-induced Disorders: Allergic Rhinitis and Chronic Urticaria
Overview
Allergic rhinitis and chronic idiopathic urticaria, chronic histamine-induced conditions, negatively and significantly impact patient health and quality of life. However, current treatment options are only modestly successful, and obstacles remain to improving outcomes. Diagnostic Work-up and Management of Histamine-induced Disorders: Allergic Rhinitis and Chronic Urticaria will provide primary care clinicians with practical, evidence-based solutions for managing the challenges of these conditions, with an emphasis on finding effective treatments, managing side effects, and ensuring patient compliance.
Objectives
Identify strategies to overcome barriers for adequate control of allergic rhinitis symptoms
Create treatment strategies to improve outcomes for patients with chronic idiopathic urticaria
Faculty
Michael J. Welch, MD
Director, Allergy & Asthma Medical Group and Research Center
Clinical Professor, Department of Pediatrics
Division of Allergy and Immunology
University of California, San Diego
San Diego, CA
Jay Portnoy, MD
Chief, Section of Allergy
Medical Director, Health Management
Professor of Pediatrics
University of Missouri-Kansas City School of Medicine
Kansas City, MO
| | | Opioid Therapy | | | Risk Assessment and Management of Pain Patients with Opioid Therapy
Overview
Opioids provide effective pain management for acute and cancer pain and are useful in treating patients with chronic non-cancer pain who have not responded to other pain management therapies. Because of potential opioid abuse, patients and physicians may be reluctant to initiate opioid therapy for pain relief. This program will examine clinical strategies and recently published guidelines to balance effective opioid therapy against the risk of opioid misuse, abuse, and diversion.
Objectives
Differentiate the concepts of misuse, abuse, diversion, and addiction as defined in the APS/AAPM Clinical Guidelines for Opioid Therapy in Chronic Non-cancer Pain
Implement effective clinical strategies for managing opioid therapy in patients with acute and chronic non-cancer pain with consideration given to risk factors according to published guidelines
Faculty
Bill McCarberg, MD
Adjunct Assistant Clinical Professor
University of California
San Diego, CA
Lynn Webster, MD
Medical Director
Lifetree Pain Clinic and Research Center
Chief of Anaesthesiology
Health South Salt Lake Surgery Center
Salt Lake City, UT
|
|
